Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2012 |
| Outros Autores: | , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10362/149794 |
Resumo: | Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010. |
| id |
RCAP_5a2bace31dbafcd776610026e4af4822 |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/149794 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
|
| spelling |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritisComparative effectivenessRAResponse predictorsReuma.pt registerTNF inhibitorsRheumatologyPharmacology (medical)Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010.Objectives: Adalimumab, etanercept and infliximab are effective TNF inhibitors (TNFis) in the treatment of RA, but no randomized clinical trials have compared the three agents. Prior observational data are not consistent. We compared their effectiveness over 1 year in a prospective cohort.Methods: Analyses were performed on subjects' first episode of TNFi use in the Rheumatic Diseases Portuguese Register, Reuma.pt. The primary outcome was the proportion of patients with European League Against Rheumatism good response sustained at two consecutive observations separated by 3 months during the first year of TNFi use. Comparisons were performed using conventional adjusted logistic regression, as well as matching subjects across the three agents using a propensity score. In addition, baseline predictors of treatment response to TNFi were identified.Results: The study cohort included 617 RA patients, 250 starting etanercept, 206 infliximab and 161 adalimumab. Good response was achieved by 59.6% for adalimumab, 59.2% for etanercept and 51.9% for infliximab (P = 0.21). The modelled probability of good response did not significantly differ across agents (etanercept vs adalimumab OR = 0.97, 95% CI 0.55, 1.71; etanercept vs infliximab OR = 1.25, 95% CI 0.74, 2.12; infliximab vs adalimumab OR = 0.80, 95% CI 0.47, 1.36). Matched propensity score analyses also showed no significant treatment response differences. Greater educational attainment was a predictor of better response, while smoking, presence of ACPA, glucocorticoid use and worse physician assessment of disease activity at baseline each predicted a reduced likelihood of treatment response.Conclusion: Over 1 year, we found no difference in effectiveness between adalimumab, etanercept and infliximab.Centro de Estudos de Doenças Crónicas (CEDOC)NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNCanhão, HelenaRodrigues, Ana MariaMourão, Ana FilipaMartins, FernandoSantos, Maria JoséCanas-silva, JoséPolido-pereira, JoaquimSilva, José Alberto PereiraCosta, José AntónioAraújo, DomingosSilva, CândidaSantos, HelenaDuarte, CátiaDa silva, José Antonio PereiraPimentel-santos, Fernando M.Branco, Jaime CunhaKarlson, Elizabeth W.Fonseca, João EuricoSolomon, Daniel H.2023-02-27T22:22:57Z2012-112012-11-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article7application/pdfhttp://hdl.handle.net/10362/149794eng1462-0324PURE: 49089688https://doi.org/10.1093/rheumatology/kes184info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-10T16:12:27ZPortal AgregadorONG |
| dc.title.none.fl_str_mv |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| title |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| spellingShingle |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis Canhão, Helena Comparative effectiveness RA Response predictors Reuma.pt register TNF inhibitors Rheumatology Pharmacology (medical) |
| title_short |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| title_full |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| title_fullStr |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| title_full_unstemmed |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| title_sort |
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis |
| author |
Canhão, Helena |
| author_facet |
Canhão, Helena Rodrigues, Ana Maria Mourão, Ana Filipa Martins, Fernando Santos, Maria José Canas-silva, José Polido-pereira, Joaquim Silva, José Alberto Pereira Costa, José António Araújo, Domingos Silva, Cândida Santos, Helena Duarte, Cátia Da silva, José Antonio Pereira Pimentel-santos, Fernando M. Branco, Jaime Cunha Karlson, Elizabeth W. Fonseca, João Eurico Solomon, Daniel H. |
| author_role |
author |
| author2 |
Rodrigues, Ana Maria Mourão, Ana Filipa Martins, Fernando Santos, Maria José Canas-silva, José Polido-pereira, Joaquim Silva, José Alberto Pereira Costa, José António Araújo, Domingos Silva, Cândida Santos, Helena Duarte, Cátia Da silva, José Antonio Pereira Pimentel-santos, Fernando M. Branco, Jaime Cunha Karlson, Elizabeth W. Fonseca, João Eurico Solomon, Daniel H. |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Centro de Estudos de Doenças Crónicas (CEDOC) NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
| dc.contributor.author.fl_str_mv |
Canhão, Helena Rodrigues, Ana Maria Mourão, Ana Filipa Martins, Fernando Santos, Maria José Canas-silva, José Polido-pereira, Joaquim Silva, José Alberto Pereira Costa, José António Araújo, Domingos Silva, Cândida Santos, Helena Duarte, Cátia Da silva, José Antonio Pereira Pimentel-santos, Fernando M. Branco, Jaime Cunha Karlson, Elizabeth W. Fonseca, João Eurico Solomon, Daniel H. |
| dc.subject.por.fl_str_mv |
Comparative effectiveness RA Response predictors Reuma.pt register TNF inhibitors Rheumatology Pharmacology (medical) |
| topic |
Comparative effectiveness RA Response predictors Reuma.pt register TNF inhibitors Rheumatology Pharmacology (medical) |
| description |
Funding Information: positions on two Pfizer sponsored trials and has directed an educational course supported by Bristol Myers Squibb. He serves as an epidemiology consultant to CORRONA. J.A.P.S. has received honoraria as a speaker or consultant and benefited from research support from several pharmaceutical companies involved in the production of biologic agents (Abbott, Amgen, MSD, Pfizer and Roche), always at sums less than E10 000. All other authors have declared no conflicts of interest. Funding Information: Funding: This work was supported by a grant from Harvard-Portugal Program HMSP-ICS/SAU-ICT/0002/ 2010. |
| publishDate |
2012 |
| dc.date.none.fl_str_mv |
2012-11 2012-11-01T00:00:00Z 2023-02-27T22:22:57Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/149794 |
| url |
http://hdl.handle.net/10362/149794 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
1462-0324 PURE: 49089688 https://doi.org/10.1093/rheumatology/kes184 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
7 application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1777303094600663040 |